消息面上，GUANZE MEDICAL宣布，要约人富德(香港)投资向控股股东收购约6.99亿股股份，占该公 司已发行股本总数约73.6%，总代价约1.75亿港元。紧接完成后，要约人及一致行动人士须按例提出无 条件现金要约，以收购该公司全部已发行股本。现金要约价每股0.25港元，较停牌前收市价1.56港元， 折让约84%。 智通财经APP获悉，GUANZE MEDICAL(02427)复牌高开逾15%，截至发稿，涨15.38%，报1.8港元， 成交额210.6万港元。 ...

GUANZE MEDICAL(02427)发布公告，公司股份将于2026年2月12日上午九时正起恢复买卖。 ...

格隆汇2月12日丨GUANZE MEDICAL(02427.HK)发布公告，该公司的股份将于今天(12/2/2026)上午九时 正起恢复买卖。 ...

智通财经APP讯，GUANZE MEDICAL(02427)发布公告，公司股份将于2026年2月12日上午九时正起恢 复买卖。 ...

GUANZE MEDICAL（02427）公布，本公司已向联交所申请股份自2026年2月12日（星期四）上午九时 正起恢复买卖。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 GUANZE MEDICAL（02427）公布，本公司已向联交所申请股份自2026年2月12日（星期四）上午九时 正起恢复买卖。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

GUANZE MEDICAL(02427)及要约人富德(香港)投资控股有限公司联合公布，董事会获售股股东告知， 于2026年1月28日，要约人(作为买方)与售股股东Meng A Capital Limited(作为卖方)订立买卖协议，以向 售股股东收购6.99亿股股份，占本公司于本联合公告日期已发行股本总数约73.60%，总代价为1.75亿港 元(相当于代价每股股份0.25港元)。 此外，本公司已向联交所申请股份自2026年2月12日(星期四)上午九时正起恢复买卖。 要约价每股要约股份0.25港元，较在最后交易日(即2026年1月26日)于联交所所报收市价每股股份1.560 港元折让约84.0%。 要约人为一间于2015年9月17日在香港注册成立的有限责任公司，主要从事股票及股权投资。于本联合 公告日期，要约人由张峻先生(张先生)及陶美萦女士(陶女士)分别最终实益拥有94%及6%。于本联合公 告日期，要约人由富德控股(集团)有限公司(一间于中国成立的公司)直接全资拥有，而富德控股(集团)有 限公司则由深圳市峻德投资有限公司(一间于中国成立的公司)(由张先生全资拥有)、张先生、深圳市富 源祥投资有限公司(一间于 ...

Group 1 - The company GUANZE MEDICAL (02427) announced a share acquisition agreement with the offeror, Fude (Hong Kong) Investment Holdings Limited, to purchase 699 million shares, representing approximately 73.60% of the company's total issued share capital, for a total consideration of HKD 175 million, equating to HKD 0.25 per share [1] - Following the completion of the acquisition, the offeror will hold 699 million shares, which will constitute approximately 73.60% of the company's issued share capital [1] - The offeror is required to make a mandatory unconditional cash offer to acquire all remaining shares of the company at a price of HKD 0.25 per share, which represents an approximately 84.0% discount compared to the last trading price of HKD 1.560 per share on January 26, 2026 [1] Group 2 - The offeror is a limited liability company registered in Hong Kong, primarily engaged in stock and equity investments, with ownership held by Mr. Zhang Jun (94%) and Ms. Tao Meiying (6%) [2] - The offeror is wholly owned by Fude Holdings (Group) Limited, which is in turn owned by Shenzhen Jun De Investment Co., Ltd., Mr. Zhang, and Ms. Tao through various ownership stakes [2] - An independent financial advisor, Softbank China Hong Kong Securities Limited, has been appointed to provide advice to the independent board committee regarding the fairness and reasonableness of the offer [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on February 12, 2026 [3]

Core Viewpoint - GUANZE MEDICAL (02427.HK) announced a share acquisition agreement where the buyer, Fude (Hong Kong) Investment Holdings, will purchase 699,164,575 shares from the selling shareholders, representing approximately 73.60% of the company's issued share capital, for a total consideration of HKD 174,791,143.75, equating to HKD 0.25 per share, which is an 84.0% discount compared to the last trading price of HKD 1.560 on January 26, 2026 [1][2] Group 1 - The buyer will hold 699,164,575 shares post-completion, amounting to about 73.60% of the total issued share capital of the company [1] - A mandatory unconditional cash offer will be made by the buyer to acquire all issued shares of the company, excluding those already owned or agreed to be acquired by the buyer and its concert parties [1] - The buyer intends to continue the existing main business of the group without making any significant changes or reallocating assets post-offer [2] Group 2 - The buyer is a limited liability company registered in Hong Kong since September 17, 2015, primarily engaged in stock and equity investments [2] - The ultimate beneficial ownership of the buyer is held by Zhang Jun (94%) and Tao Meiying (6%) [2] - The company has applied for the resumption of trading of its shares on the Hong Kong Stock Exchange starting from February 12, 2026 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本聯合公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本聯合公告僅供參考，並不構成收購、購買或認購Guanze Medical Information Industry (Holding) Co., Ltd.證券的邀請或要約或成為其中一部分，亦非於任何司法權區招攬任何表決權或批准， 亦不得在與適用法律或法規相抵觸的情況下於任何司法權區出售、發行或轉讓Guanze Medical Information Industry (Holding) Co., Ltd.證券。本聯合公告不會在構成違反有關司法權區的相關 法律的情況下於或向該司法權區發佈、刊發或派發。 FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED 富德（香港）投資控股有限公司 （於香港註冊成立的有限責任公司） GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD. （於開曼群島註冊成立的 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: Guanze Medical Information Industry (Holding) Co., Ltd. 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02427 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | ...